|
Fig. 5 Performance of selected hits in dose–response assays on adgrg6tb233c−/− mutants. Ivermectin (A) and ebastine (B) were tested in a 1.5-fold dilution series on groups of nine adgrg6tb233c−/− hypomorphic mutant embryos. Charts show the number of mutant embryos (columns 2–11) that scored 0, 1, 2, or 3 in the vcanb and mbp assays, in comparison with untreated wild-type embryos (column 1). The blue shades represent the in situ hybridization staining score for each gene. For vcanb, a pale shade indicates full rescue (reduction) of otic expression to wild-type levels (vcanb score 0; see scale), whereas the darkest shade indicates no rescue (vcanb score 3). For mbp, the darkest shade indicates full rescue (restoration) of expression around the PLLg (mbp score 3), and pale shades no rescue (mbp scores 1 or 0). Toxic effects are highlighted in red (pale, toxic (T); dark, corrosive (C; no embryos in well)). (A) Example images show lateral view of an ear from a mutant embryo treated with 22.5-μM ivermectin in the vcanb assay (A I′, score 0), and dorsal view of a mutant embryo treated with 10-μM ivermectin in the mbp assay (A II′, score 2). (B) Example images show lateral view of an ear from a mutant embryo treated with 10-μM ebastine in the vcanb assay (B I′, score 1) and dorsal image of an embryo treated with 6.67-μM ebastine in the mbp assay (B II′, score 2). Arrows mark restoration of mbp expression around the PLLg.